Posts Tagged ‘biotech ETFs’

Biotech ETFs Get Crushed

April 10th, 2014

technology dropRick Pendergraft: By all accounts, 2013 was a great year for stocks. Even with the S&P gaining over 26% on the year, the biotech sector stood out as a top performer. The iShares Biotech Index Fund (NASDAQ:IBB) gained 60% on the year. Read more…


It’s Going To Be A Bumpy Ride For Biotech

April 10th, 2014

biotechBiotech stocks sailed into 2014 backed by a favorable wind, but springtime has stymied the sector in confused seas. Companies on The Life Sciences Report’s 2014 Biotech Watchlist have hit the doldrums along with the rest, as faithful followers of the portfolio Read more…


Biotech Stocks With Exciting Development Projects

April 10th, 2014

biotechnologyKeith Markey, veteran analyst and science director of Griffin Securities, tells us the 2014 pipeline calendar positively glows with important milestones that could ignite portfolios. In this interview with The Life Sciences ReportMarkey talks about four powerful biotech Read more…


Bubble Only Bursting For Biotech & Internet Stocks?

April 9th, 2014

dollar money bubbleDespite signs that most of the U.S. economic softness of the last three months was weather related, equities have struggled to push higher lately. The recent sluggish performance of U.S. stocks, especially those in the biotechnology and technology industries, Read more…


GlaxoSmithKline plc (ADR) (GSK): Significant Upside For The Stock

April 9th, 2014

technical chart lookRick Pendergraft: Pharmaceutical giant GlaxoSmithKline plc (ADR) (NYSE:GSK) caught my attention last night as the stock has formed an island bottom. This pattern is a reliable reversal sign in and of itself, but there are several other factors Read more…


Gilead Sciences, Inc. (GILD): Biotech Bubble or Buying Opportunity?

April 8th, 2014

dollar money bubbleTyler Laundon: Two weeks ago Gilead Sciences (NASDAQ:GILD) received a letter from three members of Congress. In that letter, lawmakers asked for a briefing from Gilead regarding the pricing of its new hepatitis C drug Sovaldi, which Gilead is selling for $1,000 per pill. Read more…


Bringing Big Finance To Little Biotechs

April 4th, 2014

biotechnologyBiotech companies don’t come into the world fully formed. Like most fledglings, they need guidance to grow, prosper and eventually thrive in public markets. Venture capitalist Ran Nussbaum of the Pontifax Group nurtures tiny biotech and medtech startups, Read more…


Is Biotech Getting Bubbly?

April 1st, 2014

wealthVeteran biotechnology analyst Michael King of JMP Securities has seen drug development evolve from hit-or-miss to the sophisticated, high-throughput discovery techniques in place today. He understands the sector, the entrepreneurs and the valuations Read more…


Biotech ETFs To Buy On The Dip

March 31st, 2014

biotechnologyThe high flying, and top performing, sector of 2013 – biotech – delivered impressive gains last year, on the back of increasing mergers and acquisition activities, expansion into emerging markets, Read more…


ETFs To Watch As Obamacare Hits Deadline

March 31st, 2014

healthcare-etfsDespite the rocky start and a plethora of technical issues, the Affordable Care Act (often known as Obamacare) saw a surge in enrollment in the final days of its first year program. More than 6 million Americans (as of March 27) have signed Read more…


Getting Technical With The Biotech ETF

March 27th, 2014

technical chart lookMorpheus Trading: Once again, leading tech stocks and small cap stocks were hit hard on big volume Wednesday. The Nasdaq dropped 1.4%, closing below the 50-day MA and at the lows of the session (ugly!). The small cap Russell 2000 and Nasdaq 100 Read more…


Key Market News You Can Trade Off

March 25th, 2014

investMitchell Clark: Endocyte, Inc. (NASDAQ:ECYT) is a micro-cap biotechnology company that just doubled in value on the stock market. Read more…


ETF Impact On The Biotech Sell-Off

March 24th, 2014

biotechnologySweta Killa: The hot and the soaring biotechnology corner of the broad U.S. healthcare market suffered the steepest decline since October 2011 in Friday’s session. The worst sell-off came after U.S. lawmakers raised concerns on Gilead Sciences (NASDAQ:GILD) Read more…


The iShares NASDAQ Biotechnology Index (ETF) Is Getting Crushed

March 24th, 2014

sellbuyMorpheus Trading: Last Friday’s ugly selloff in the Nasdaq Composite was much like the price and volume action on March 13, as turnover spiked well above the 50-day volume average (although volume inflated last Friday), while the price action formed another bearish Read more…


Can Healthcare ETFs Stay Hot In 2014?

March 23rd, 2014

new etfsSome comforting economic data in the U.S. including solid job reports, which in turn spurred faster tapering, and the apparently calming tensions between Russia and Ukraine once again Read more…


Copyright 2009-2014 WBC Media, LLC